期刊文献+

罗格列酮与胰岛素联用治疗2型糖尿病的观察

下载PDF
导出
摘要 目的:观察罗格列酮对已使用较大剂量胰岛素仍未满意血糖控制的2型糖尿病的疗效观察。方法:将80例胰岛素治疗日剂量大于50单位的2型糖尿病患者随机分为两组,观察组在胰岛素基础上加用罗格列酮8mg,qd,对照组继续胰岛素治疗,治疗16周,治疗前后进行空腹血糖、餐后血糖、糖化血红蛋白、空腹胰岛素(FIns)、C肽水平及胰岛素日剂量的测定。结果:观察组能显著降低患者血糖和糖化血红蛋白,降低FIns、C肽水平,胰岛素日剂量也明显减少(P<0.01),且无肝肾功能损害发生。结论:罗格列酮联合胰岛素治疗能有效长期地控制血糖,并减少胰岛素用量、减轻胰岛素抵抗。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2007年第8期1126-1126,共1页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献3

  • 1纪立农.胰岛素增敏剂及其应用前景[J].当代医学,2001,7(2):25-30. 被引量:9
  • 2Saltidel AR,Olefsky JM.Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes[J].Diabetes,1996,45:1661.
  • 3Henry RR.Thiazolidinedions[J].Endocrinol Metab Clin North Am,1997,26:553.

二级参考文献10

  • 1Fujiwara T,Horikosh H.Troglitazone and related compounds: therapeutic potential beyond diabetes[].Life Sciences.2000
  • 2Maggs DG,Buchanan TA,Burant CF. et al.Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus:a randomized, double-blind, placebocontrolled trial[].Annal of International Medicine.1998
  • 3Glazer NB. et al.Pioglitazone effects on glycemic control and lipids. e[].Western Journal of Medicine.2001
  • 4Taylor SI.Deconstructing type 2 diabetes[].Cell.1999
  • 5Claire M. et al.The hormone resistin links obesity to diabetes[].Nature.2001
  • 6Flier J.The missing link with obesity[].Nature.2001
  • 7Olefsky JM.Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists[].The Journal of Clinical Investigation.2000
  • 8Kahn CR,et al.Unraveling the mechanism of action of thiazolidinedions[].The Journal of Clinical Investigation.2000
  • 9Lowell BB.PPAR γ: an essential regulator of adipogenesis and modulator of fat cell function[].Cell.1999
  • 10YT Kruszynska,JG Yu,JM Olefsky,BE Sobel.Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects[].Diabetes.2000

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部